GlassScriptPhysician profile
Lawrence C Anaya
NPI 1245395649
$4,655.23
in general payments reported to CMS, 2019-2025
41 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $812 · 2021: $129 · 2022: $193 · 2023: $589 · 2024: $894 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $911.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $774.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $371.28 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $296.13 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $264.92 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $251.72 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $175.88 | 2019-2020 | |
| Grifols USA, LLC | $171.46 | 2019-2024 | Prolastin-C Liquid |
| Pfizer INC. | $128.21 | 2019-2025 | |
| Astellas Pharma US INC | $119.70 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.07 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $92.19 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $85.64 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.70 | 2019-2024 | Glassia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.22 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Anaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.